BioSeek and Dainippon Sumitomo Pharma (DSP) signed an agreement for R&D in inflammation and metabolic diseases. BioSeek will apply its BioMAP® Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP’s discovery programs.
BioMAP Systems are a series of human primary cell-based assays designed to replicate cell and pathway interactions present in human disease biology. BioMAP profiling provides insight into human pharmacological properties of compounds, including characterization of biological drug function, on- and off-target activities, and biomarker identification.
“The BioMAP platform represents a very compelling approach to applying human systems biology to pharmaceutical research and development,” remarks Yuichi Yokoyama, M.D., executive director at DSP. “BioMAP Systems deliver otherwise difficult-to-obtain human biological information, which will help us prioritize leads and candidates.”